Regulation of epithelial barrier function by the inflammatory bowel disease candidate gene, PTPN2

被引:35
|
作者
McCole, Declan F. [1 ]
机构
[1] Univ Calif San Diego, Div Gastroenterol, Dept Med, Sch Med, La Jolla, CA 92093 USA
来源
BARRIERS AND CHANNELS FORMED BY TIGHT JUNCTION PROTEINS I | 2012年 / 1257卷
关键词
IFN-gamma; STAT proteins; claudin-2; Crohn's disease; TIGHT JUNCTION PROTEINS; INTERFERON-GAMMA; IFN-GAMMA; LOCI; EXPRESSION; CLAUDIN-2; PERMEABILITY; DYSFUNCTION; MULTIPLE; RECEPTOR;
D O I
10.1111/j.1749-6632.2012.06522.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein tyrosine phosphatase nonreceptor type 2 (PTPN2) has been identified as an inflammatory bowel disease (IBD) candidate gene. However, the mechanism through which mutations in the PTPN2 gene contribute to the pathogenesis of IBD has not been identified. PTPN2 acts as a negative regulator of signaling induced by the proinflammatory cytokine, interferon-gamma (IFN-gamma). IFN-gamma is known not only to play an important role in the pathogenesis of Crohn's disease (CD), but also to increase permeability of the intestinal epithelial barrier. We have shown that PTPN2 protects epithelial barrier function by restricting the capacity of IFN-gamma to increase epithelial permeability and prevent induction of expression of the pore-forming protein, claudin-2. These data identify an important functional role for PTPN2 as a protector of the intestinal epithelial barrier and provide clues as to how PTPN2 mutations may contribute to the pathophysiology of CD.
引用
收藏
页码:108 / 114
页数:7
相关论文
共 50 条
  • [21] A Direct Effect of Sex Hormones on Epithelial Barrier Function in Inflammatory Bowel Disease Models
    van der Giessen, Janine
    van der Woude, C. Janneke
    Peppelenbosch, Maikel P.
    Fuhler, Gwenny M.
    CELLS, 2019, 8 (03)
  • [22] Whole genome sequencing identifies enriched PTPN2 mutation frequency in patients with primary sclerosing cholangitis and inflammatory bowel disease
    Kiely, C.
    Whiley, P.
    Shackel, N.
    Jiang, S.
    Cook, M.
    Pavli, P.
    O'Brien, C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 114 - 114
  • [23] Analysis of a positional candidate gene for inflammatory bowel disease
    Stokkers, P
    Huibregtse, K
    Leegwater, AC
    Reitsma, PH
    Tytgat, GN
    Vandeventer, SJ
    GASTROENTEROLOGY, 1999, 116 (04) : A825 - A825
  • [24] Epithelial contribution to barrier function and carcinogenesis in the GIα2-deficient mouse model of inflammatory bowel disease
    Edwards, Robert A.
    Davis, Jennifer
    GASTROENTEROLOGY, 2006, 130 (04) : A555 - A555
  • [25] Analysis of a positional candidate gene for inflammatory bowel disease: NRAMP2
    Stokkers, PCF
    Huibregtse, K
    Leegwater, AC
    Reitsma, PH
    Tytgat, GNJ
    van Deventer, SJH
    INFLAMMATORY BOWEL DISEASES, 2000, 6 (02) : 92 - 98
  • [26] Lithocholic acid Regulates colonic epithelial barrier function and apoptosis: Implications for inflammatory bowel disease
    Lajczak-Mc Ginley, Natalia
    Smyth, Jessica
    Fallon, Ciara
    Clerkin, Caoimhe
    Keely, Stephen J.
    FASEB JOURNAL, 2019, 33
  • [27] Activation of Nf-kappab is critical for maintenance of the epithelial barrier function in inflammatory bowel disease
    Inoue, S
    Nakase, H
    Ueno, S
    Uza, N
    Kido, M
    Kitamura, H
    Kiriya, K
    Oohashi, S
    Asada, M
    Kawasaki, K
    Tamaki, H
    Fukui, T
    Matsuura, M
    Nishio, A
    Chiba, T
    GASTROENTEROLOGY, 2005, 128 (04) : A212 - A213
  • [28] AK155: A CANDIDATE GENE FOR INFLAMMATORY BOWEL DISEASE
    Jennings, J. S. R.
    Hamlin, J.
    Robinson, P. A.
    Hull, M. A.
    Howdle, P. O.
    Markham, A. F.
    GUT, 2010, 59 : A86 - A87
  • [29] PTPN2, a Candidate Gene for Type 1 Diabetes, Modulates Interferon-γ-Induced Pancreatic β-Cell Apoptosis
    Moore, Fabrice
    Colli, Maikel L.
    Cnop, Miriam
    Esteve, Mariana Igoillo
    Cardozo, Alessandra K.
    Cunha, Daniel A.
    Bugliani, Marco
    Marchetti, Piero
    Eizirik, Decio L.
    DIABETES, 2009, 58 (06) : 1283 - 1291
  • [30] SDH, a novel diarylheptane compound, is a potential treatment for inflammatory bowel disease by restoring epithelial barrier function
    Yang, Fei
    Zhu, Xiaoqiang
    Li, Liu
    Wang, Yanping
    Xie, Qing
    Cao, Yu
    Yu, Yunhui
    Zhang, Minjie
    Li, Dong
    Li, Ling
    Liu, Zhongtian
    Zhang, Biyan
    Chen, Zijun
    Deng, Shiping
    Li, Yunsen
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 151